ELSEVIER
SAUNDERS

Infect Dis Clin N Am 17 (2003) 801–816

INFECTIOUS
DISEASE
CLINICS
of North America

Cumulative Index 2003

Volume 17

March	FUNGAL INFECTIONS, PART II: RECENT ADVANCES IN DIAGNOSIS, TREATMENT, AND PREVENTION OF CUTANEOUS AND ENDEMIC MYCOSES, pages 1–226
June	URINARY TRACT INFECTIONS, pages 227–478
September	CLINICAL IMPLICATIONS OF ANTIMICROBIAL PHARMACOKINETICS, pages 479–678
December	HOSPITAL-ACQUIRED PNEUMONIA: EUROPEAN PERSPECTIVE, pages 679–816

Note: Page numbers of article titles are in **boldface** type.

A

Abdominal sepsis, treatment failures in patients with ventilator-associated pneumonia due to, 760

Abscess(es)
- in invasive mycosis diagnosis, 138
- pararenal, radiologic evaluation of, 441–443
- perinephric, UTIs and, 348–349
- perirenal, radiologic evaluation of, 441–443
- renal, radiologic evaluation of, 441–443
- treatment failures in patients with ventilator-associated pneumonia due to, 759

Acute respiratory distress syndrome (ARDS), treatment failures in patients with ventilator-associated pneumonia due to, 761

Adhesion(s), in UTI pathogenesis, 262–265

Age, as factor in aminoglycoside dosing, 511–513

Aminoglycoside(s), **503–528**
- cellular uptake and disposition of, 620–621
- dosing of
  - by age, 511–513
  - by weight, 513–514
  - during pregnancy, 517–518
  - in conventional infections, 511–514
  - in cystic fibrosis, 518
  - in dialysis patients, 516–517
  - in dosing schedules, 514–519
  - in endocarditis, 518–519
  - in neonates, 517
  - in renal impairment, 514–516
  - in special situations, 514
  - once-daily, move to, 510–511
- monitoring of, 519–521
  - area-under-the curve methods in, 520–521
  - Bayesian methods in, 521
  - single-level methods in, 520
- pharmacodynamics of, 505–507
  - human studies in, 506–507
  - in vitro, 505–506
- pharmacokinetic properties of, 503–505
- toxicodynamics of, 507–510
  - auditory toxicity, 509–510
  - nephrotoxicity, 507–509
  - neuromuscular blockade, 510
  - ototoxicity, 509
  - vestibular toxicity, 510

Amphotericin B
- for chromoblastomycosis, 79
- for mycetoma, 80–81
- for sporotrichosis, 75–76

Amphotericin B deoxycholate
- adverse effects of, 162–163
- antifungal activity of, 161
- clinical pharmacology of, 160–163
- dosing of, 163
- drug interactions with, 163

0891-5520/04/$ - see front matter © 2004 Elsevier Inc. All rights reserved.
doi:10.1016/S0891-5520(04)00013-3

Amphotericin (*continued*)
indications for, 163
mechanism of action of, 160
pharmacodynamics of, 162
pharmacokinetics of, 162
therapeutic monitoring of, 163

Amphotericin B lipid formulations
antifungal efficacy of, 164
clinical pharmacology of, 164–166
dosing of, 164–166
indications for, 164–166
pharmacokinetics of, 164
physicochemical properties of, 164
safety of, 164

Anidulafungin, clinical pharmacology of, 177–181

Anti-bacterial agents, pharmacodynamics of, **479–501**
clinical applications of, 489–491
glycopeptide antibiotics, 491–494
ß-lactam antibiotics, 483–491
linezolid, 494–495

Antibiotic(s)
concentration–effect relationships of, in breakpoint selection for susceptibility testing, 581–584
development of, pharmacodynamics in, 592–594
for hospital-acquired pneumonia, **727–737.** *See also Hospital-acquired pneumonia, antibiotics for.*
glycopeptide. *See Glycopeptide antibiotics.*
inappropriate, treatment failures in patients with ventilator-associated pneumonia due to, 758
intracellular pharmacodynamics of, **615–634**
aminoglycosides, 620–621
cellular uptake and disposition of, 618–621
described, 621–628
fluoroquinolones, 620
ß-lactams, 618
macrolides, 619–620
ß-lactam, pharmacodynamics of
in animals, 483–487
in humans, 487–489
polyene, clinical pharmacology of, 160–166
recent developments in, **739–751**
daptomycin, 746–747
duration of treatment with, 745–746
for gram-positive infections, 740–743
linezolid, 741–743
quinopristin-dalfopristin, 740–741
for hospital-acquired pneumonia, fluoroquinolones, 743–745
garenoxacin, 748
oritavancin, 748
sitafloxacin, 748
tigecycline, 747

Antibiotic resistance, emerging
in acute uncomplicated cystitis, 244–248. *See also Cystitis, acute uncomplicated.*
in acute uncomplicated pyelonephritis, 249
in urinary tract pathogens, **243–261**

Antifungal agents
clinical pharmacodynamics of, **635–649**
impact of antimicrobial pharmacodynamics on, 638–640
pharmacodynamic parameter magnitude in, 638
triazole antifungals, 640
pharmacodynamic parameter predictor of efficacy in, 636–637
pharmacodynamic patterns of activity in, 635–636
triazoles, 640–644
unanswered questions related to, 645
for coccidioidomycosis, 54–55
oral, side effects of, 109–110

Antifungal compounds, clinical pharmacology of, **159–188**
Amphotericin B deoxycholate, 160–164
Amphotericin B lipid formulations, 164–166
antifungal triazoles, 167–177
echinocandin lipopeptides, 177–181
flucytosine, 166–167
future directions in, 181
liposomal nystatin, 166
polyene antibiotics, 160–166

Antifungal triazoles
antifungal activity of, 169
clinical pharmacology of, 167–177
fluconazole, 169–171
itraconazole, 172–175
mechanism of action of, 169
resistance to, 169
second-generation, 175–177
pharmacology of, 175–176

Antigen testing
in invasive candidiasis, 151
in noninvasive aspergillosis, 151

Anti-HIV drugs
clinical use of
target concentrations in, 665–666
therapeutic drug monitoring in, 665–668
role of, 667–668
trials of, 666–667
drug transport proteins in, 654–655
inhibitory quotient in, 653
metabolism of, 653–654
NNRTIs, 658
NRTIs, 657–658
pharmacodynamics of, **651–674**
efficacy in, 657–658
principles of, 651–656
pharmacokinetics principles of, 651–656
protease inhibitors, 659–662
protein binding in, 652–653
resistance to, emergence of, 664–665
toxicity of, 662–664

Antimicrobial agents. *See Antibiotic(s).*

Antimicrobial resistance, in acute uncomplicated cystitis, 308–310

Antimicrobial tissue concentrations, **599–613**
measurement of
imaging techniques in, 608
microdialysis in, 604–608
skin blister and saliva techniques in, 604
techniques for, 603–608
protein binding in, 601–603
tissue distribution in, issues related to, 603

Antiretroviral agents, pharmacokinetics of, 652

ARDS. *See Acute respiratory distress syndrome (ARDS).*

Aspergillosis, invasive, antigen testing in, 151

Aspergillus infections, in solid organ transplant recipients
epidemiology of, 113–118
risk factors for, 113–118

Atelectasis, treatment failures in patients with ventilator-associated pneumonia due to, 760–761

Auditory toxicity, of aminoglycosides, 509–510

Azalide(s), **563–577**
microbiologic activity of, 564–565
pharmacodynamic models of, 567–569
application of, 573–574
pharmacodynamic(s) of, 569–570
clinical implications of, 570–573
pharmacokinetics of, 565–567

B

Bacteria, in cells, entry and fate of, 616–618

Bacteriuria, asymptomatic, **367–394**
during pregnancy, treatment of, 339–340
in children, 372–373
in diabetics, 379–380
in healthy, nonelderly populations, 372–376
in persons with chronic medical conditions, 379–382
in persons with urologic devices, 383–385
in pregnant women, 374–376
in premenopausal, nonpregnant women, 373
in renal transplant patients, 381–382
in spinal cord–injured patients, 380–381
in the elderly, 376–378
in young men, 376
pathogenesis of, 368–369
screening for, 369–372
treatment of, surgical, 385–386

Bayesian methods, in aminoglycoside monitoring, 521

Biofilm(s), catheter-associated UTIs and, **411–432.** *See also Urinary tract infections (UTIs), catheter-associated.*
pathogenesis of, 413–415

Bladder
bacterial colonization of, in UTI prevention, 466
neuropathic, UTIs in, 341–344

Blastomyces dermatitidis, blastomycosis caused by, 22–23

Blastomycosis, **21–40**
clinical manifestations of, 25–30
described, 21
diagnosis of, 30–31
ecology of, 23
epidemiology of, 23
organism causing, 12–3
pathogenesis of, 23–25
prevention of, 35
treatment of, 31–35
virulence of, 23–25

Blood cultures, in invasive mycosis diagnosis, 136

Bone marrow, in invasive mycosis diagnosis, 137

Bronchitis, suppurative, treatment failures in patients with ventilator-associated pneumonia due to, 759

Broncholithiasis, in histoplasmosis, 4

Bronchoscopy, for nosocomial pneumonia in immunosuppressed patients, 787–789

C

Candida infections, in solid organ transplant recipients
epidemiology of, 113–118
risk factors for, 113–118

Candidiasis, invasive, antigen testing in, 151

Caspofungin, clinical pharmacology of, 177–181

Catheter(s)
external, in prevention of catheter-associated UTIs, 422
indwelling
chronic, asymptomatic bacteriuria in persons with, 384
short-term, asymptomatic bacteriuria in persons with, 383–384
infection related to, treatment failures in patients with ventilator-associated pneumonia due to, 760
suprapubic, in prevention of catheter-associated UTIs, 422–424
urinary
misuse of, 416–417
use of, 416–417

Catheter tip, intravascular, in invasive mycosis diagnosis, 137

Catheterization, intermittent, in prevention of catheter-associated UTIs, 422

Central nervous system (CNS), histoplasmosis of, 6

CHF. *See Congestive heart failure (CHF).*

Children
acute pyelonephritis in, radiologic evaluation of, 439–441
asymptomatic bacteriuria in, 372–373
UTIs in, **353–365.** *See also Urinary tract infections (UTIs), in infants and children.*

Chromoblastomycosis
clinical manifestations of, 71–72
epidemiology of, 60–62
laboratory diagnosis of, 67
pathogenesis of, 65–66
treatment of, 76–79

Chronic prostatitis–chronic pelvic pain syndrome (CP-CPPS), 400–401
inflammatory, 401
noninflammatory, 401

Ciprofloxacin, for acute uncomplicated cystitis, 317–318

Coccidioidomycosis, **41–57**
clinical manifestations of, 44–45
diagnosis of, 48–49
diffuse pneumonia and, 45–46
disseminated, 46–47
during pregnancy, 54
endemic areas for, 41–42
epidemics of, 43
extrapulmonary, 46–47
historical background of, 41
host defense in, 43–44
in HIV patients, 54
in transplant patients, 54
incidence of, 42
pathogenesis of, 43–44
prevalence of, 42
prevention of, 55
risk factors for, 42–43
treatment of, 49–54
antifungal agents in, 54–55
immunotherapy in, 54
vaccine for, development of, 55

Community-acquired UTIs, **303–332.** *See also Urinary tract infections (UTIs), community-acquired.*

Computed tomography (CT)
in pyelonephritis, 434–436, 438–439
emphysematous, 443–445
thoracic, for nosocomial pneumonia in immunosuppressed patients, 789

Congestive heart failure (CHF), treatment failures in patients with ventilator-associated pneumonia due to, 760–761

Contusion(s), pulmonary, treatment failures in patients with ventilator-associated pneumonia due to, 762

Corneal scrapings, in invasive mycosis diagnosis, 137

CP-CPPS. *See Chronic prostatitis–chronic pelvic pain syndrome (CP-CPPS).*

Cranberry, in UTI prevention, 459–462

Cryosurgery, for chromoblastomycosis, 76

Cryptococcosis, in invasive mycosis
diagnosis, 150

Cryptococcus neoformans, in solid organ
transplant recipients, 119

CT. *See Computed tomography (CT).*

Cutaneous infections, **87–112.** *See also*
specific types, e.g., *Dermatophytosis.*
antifungal agents for, side effects of,
109–110
dermatophytosis, 87–100
onychomycosis, 100–107
tinea versicolor, 107–109

CXCR1 gene, SNPs in, 290–291

Cyst(s), UTI, infected, radiologic evaluation
of, 447

Cystic fibrosis, aminoglycosides for, 518

Cystitis
acute, in postmenopausal women, 325
acute uncomplicated, 307–321
antimicrobial resistance to,
308–310
impact on treatment outcomes,
309–310
prevalence of, 308–309
TMP-SMX, predictors of infec-
tion or colonization with,
310
diagnosis of, 307–308
emerging antibiotic resistance to,
244–248
fosfomycin, 248
ß-lactams, 248
nitrofurantoin, 247–248
recurrence of, approach to,
325–326
treatment of, 310–321
fluoroquinolones in, 316–318
fosfomycin in, 318
ß-lactams, 313–314
nitrofurantoin in, 314–316
overview of, 310–312
recommendations for,
318–321
TMP-SMX in, 312–313
uncomplicated, emerging antibiotic
resistance to
fluoroquinolones, 246–247
TMP-SMX, 244–246

Cytokine(s)
against invasive fungal infections,
199–200
in neutropenic and nonneutropenic
hosts, 195–199
opportunistic fungi–related, properties
of, 191–195
Th1, 193–194
Th2, 194
with granulocyte transfusions, in
invasive fungal infections,
204–207

D

Daptomycin, 746–747

Dermatophytosis, **87–100**
clinical manifestations of, 89–98
described, 87–88
epidemiology of, 88–89
host defense of, 89
laboratory diagnosis of, 98
pathogenesis of, 89
prevention of, 13–14
treatment of, 13–14

Diabetes mellitus
asymptomatic bacteriuria in, 379–380
UTIs in patients with, 344–345

Dialysis, patients on, aminoglycosides in,
516–517

Drug(s), fever due to, treatment failures in
patients with ventilator-associated
pneumonia due to, 762

Drug transport proteins, in anti-HIV drugs,
654–655

E

Echinocandin lipopeptides
adverse effects of, 180
antifungal activity of, 178
clinical pharmacology of, 177–181
clinical studies of, 180–181
drug interactions with, 180
pharmacodynamics of, 178
pharmacokinetics of, 178–180

Echinococcus, UTIs resulting from, 348

Edema, pulmonary, postpneumonectomy,
treatment failures in patients with
ventilator-associated pneumonia due
to, 762

Elderly, asymptomatic bacteriuria in,
376–378
in community residents, 376–378
in long-term care facility residents, 378

Embolism, pulmonary, treatment failures in
patients with ventilator-associated
pneumonia due to, 761

Emphysematous pyelonephritis, 345–346
radiologic evaluation of, 443–445

Empyema, treatment failures in patients with ventilator-associated pneumonia due to, 759

Endocarditis, aminoglycosides in, 518–519

Enterococcus(i), vancomycin-resistant, in complicated UTIs, 249–250

Entobacteriaceae, UTIs in infants and children due to, 354–355

Escherichia coli, extraintestinal pathogenic, virulence factors of, 261–262

Eumycetoma, treatment of, 79

External catheters, in prevention of catheter-associated UTIs, 422

F

Fever, drug-related, treatment failures in patients with ventilator-associated pneumonia due to, 762

Fibrosing mediastinitis, in histoplasmosis, 4

Fluconazole
adverse effects of, 170–171
clinical indications for, 171
clinical pharmacology of, 169–171
dosing of, 171
drug interactions with, 171
for sporotrichosis, 74
pharmacodynamics of, 169–170
pharmacokinetics of, 170

Flucytosine
clinical pharmacology of, 166–167
for chromoblastomycosis, 78

Fluoroquinolone(s)
cellular uptake and disposition of, 620
for acute uncomplicated cystitis, 316–318
for hospital-acquired pneumonia, 743–745
resistance to
in acute uncomplicated cystitis, 246–247
in complicated UTIs, 250–251

Fosfomycin
for acute uncomplicated cystitis, 318
resistance to, in acute uncomplicated cystitis, 248

Fungal cultures, in invasive mycosis diagnosis, assessment of, 146

Fungal infections
in solid organ transplant recipients, **113–134.** *See also* specific transplant recipients, e.g., *Liver transplant recipients.*
Apergillus infections, 113–118
Candida infections, 113–118
clinical manifestations of, 121–123
Cryptococcus neoformans and, 119
diagnosis of, 123–124
endemic fungi and, 118–119
epidemiology of, 113–119
geographically restricted fungi and, 118–119
management of, 125–130
mycelial fungi and, 118
pathogenesis of, 119–121
risk factors for, 113–119
invasive, immunomodulation of, **189–215.**
See also Invasive fungal infections, immunomodulation of.
UTI–related, radiologic evaluation of, 451–453

Fungemia, in invasive mycosis diagnosis, detection of, 145

Fungus(i)
molecular epidemiology of, 153
opportunistic, cytokines related to, properties of, 191–195

G

Garenoxacin, 748

Gene(s)
CXCR1, SNPs in, 290–291
metabolic, in UTI pathogenesis, 267

Genitourinary tuberculosis, UTIs resulting from, 346–348

Glycopeptide antibiotics,
pharmacodynamics of, 491–494
clinical applications of, 493–494
in animals, 491–493
in humans, 493

Granulocyte colony–stimulating factor, 192–193

Granulocyte transfusions, in invasive fungal infections, 200–204
clinical efficacy of, 201
complications of, 203
future directions in, 203–204
harvesting of, 202–203
with cytokines, 204–207

Granulocyte-macrophage colony–stimulating factor, 5

Granuloma(s), mediastinal, in histoplasmosis, 3–4

H

Heart transplant recipients
  Aspergillus infections in, 117
  Candida infections in, 117

Hematopoietic growth factors, 191–193

Hemorrhage, pulmonary, treatment failures in patients with ventilator-associated pneumonia due to, 761

Histoplasmosis, **1–19**
  clinical manifestations of, 3–8
    adrenal involvement, 6–7
    asymptomatic infection, 3
    broncholithiasis, 4
    CNS, 6
    endocarditis, 7
    fibrosing mediastinitis, 4
    mediastinal granuloma, 3–4
    pericarditis, 5
    pulmonary, 3–5
    rheumatologic syndromes, 5
    sarcoiditis, 8
  CNS, 6
  disseminated
    clinical manifestations of, 5–8
    laboratory findings suggestive of, 7
    radiographic findings suggestive of, 7
    uncommon manifestations of, 7
  epidemiology of, 1–2
  in invasive mycosis diagnosis, 150
  laboratory diagnosis of, 8–10
  pathogenesis of, 2
  presumed ovular, 8
  prevention of, 15–16
  pulmonary, chronic, 4–5
  treatment of, 10–15

HIV infection. *See Human immunodeficiency virus (HIV) infection.*

Hospital-acquired pneumonia, **679–696.** *See also Ventilator-associated pneumonia.*
  antibiotics for, **727–737**
    clinical setting for, 729–730
    de-escalation of, 732–734
    direct examination of pulmonary secretions after administration of, information given by, 731
    duration of, 735
    historical background of, 727–728
    intrinsic antibacterial activities of, 731–732
    monotherapy vs. combination therapy, 734
    routine surveillance culture results of, 730–731
    selection of, factors contributing to, 729–732
  defined, 708–709
  described, 679
  diagnosis of, **707–716, 717–726**
    clinical strategy alone vs. bacteriologic strategy based on bronchoscopic-protected specimen brush or BAL, 720
    clinical strategy alone vs. clinical strategy with short-course antibiotic therapy in, 719–720
    clinical strategy associated with qualitative cultures of endotracheal aspirates vs. bacteriologic strategy based on bronchoscopic techniques in, 720–722
    clinical strategy associated with quantitative cultures of endotracheal aspirates vs. bacteriologic strategy based on bronchoscopic techniques in, 722
    historical background of, 717–719
    synthesis in, 722–724
  prevention of, **771–782**
    body position in, 779
    enteral feeding modulation in, 777–778
    oropharyngeal decontamination in, 776
    quidelines in, 771–772
    selective decontamination of digestive tract in, 772–775
    stress-ulcer prophylaxis in, 776–777
    subglottic secretion drainage in, 778
    systemic, 775–776
    reviews of, 771–772

Host response, factors related to, treatment failures in patients with ventilator-associated pneumonia due to, 762–763

Host susceptibility, to UTIs, genetic determinants of, 286–292

Human immunodeficiency virus (HIV) infection
coccidioidomycosis and, 54
pharmacokinetics of, 655–656

I

Imaging, in antimicrobial tissue concentration measurement, 608

Immunotherapy, for coccidioidomycosis, 54

Infant(s), UTIs in, **353–365.** *See also Urinary tract infections (UTIs), in infants and children.*

Inhibitory quotient, in anti-HIV drugs, 653

Interferon-gamma, 194

Interleukin(s)
IL-8 receptor expression, in pyelonephritis-prone children, 289
IL-8 receptor knock-out, acute pyelonephritis and renal scarring due to, 287
IL-15, 194

Intermittent catheterization, in prevention of catheter-associated UTIs, 422

Intravascular catheter tip, in invasive mycosis diagnosis, 137

Intubated patient, pneumonia in, risk factors for, **697–705.** *See also Pneumonia(s), in intubated patients.*

Invasive aspergillosis, antigen testing in, 151

Invasive candidiasis, antigen testing in, 151

Invasive fungal infections, immunomodulation of, **189–215**
cytokines against, 199–200
genetic risks associated with, 190–191
granulocyte transfusions and, 200–204
therapy-induced risks associated with, 190

Invasive mycoses, laboratory diagnosis of, **135–158**
abscess in, 138
antifungal susceptibility in, 152–153
blood cultures in, 136
bone marrow in, 137
corneal scrapings in, 137
cryptococcosis, 150
culture on solid media in, 145–146
direct detection in, 138–143
fungal culture assessment in, 146
fungemia detection in, 145
histopathologic diagnosis in, 143–145
histoplasmosis, 150
intravascular catheter tip in, 137
mold identification in, 147–149
molecular detection in, 150–152
non–culture-based methods in, 149–150
1,3-ß-D-glucan in, 152
reference laboratory's role in, 153
respiratory tract in, 137
specimen collection in, 136–138
sterile fluids in, 136
stool sample in, 138
tissue biopsy in, 137
transport in, 136–138
urine in, 137–138
wounds in, 138
yeast identification in, 147–149

Itraconazole
adverse effects of, 173
clinical indications for, 174–175
clinical pharmacology of, 172–175
dosing of, 174–175
drug interactions with, 173–174
for chromoblastomycosis, 77–78
for sporotrichosis, 75
pharmacodynamics of, 172
pharmacokinetics of, 172–173
therapeutic monitoring of, 175

J

Jock itch, 94

K

Ketoconazole, for sporotrichosis, 74

Ketolide(s), **563–577**
microbiologic activity of
pharmacodynamic models of, 567–569
application of, 573–574
pharmacodynamic(s) of, 569–570
clinical implications of, 570–573
pharmacokinetics of, 565–567

L

ß-Lactam(s)
cellular uptake and disposition of, 618
for acute uncomplicated cystitis, 313–314
pharmacodynamics of
clinical applications of, 489–491
in animals, 483–487
in humans, 487–489
resistance to, in acute uncomplicated cystitis, 248

ß-Lactamases, extended-spectrum, resistance to, in complicated UTIs, 250

Lactobillus(i), in UTI prevention, 462–464

Linezolid
for gram-positive infections, 741–743
pharmacodynamics of, 494–495

Lipopolysaccharide, in UTI pathogenesis, 267

Liposomal nystatin, clinical pharmacology of, 166

Liver transplant recipients
Aspergillus infections in, 113–115
Candida infections in, 113–115

Long-term care facility residents, asymptomatic bacteriuria in, 378

Lung biopsy, for nosocomial pneumonia in immunosuppressed patients, 789–790

Lung transplant recipients
Aspergillus infections in, 115–117
Candida infections in, 115–117

M

Macrolide(s), **563–577**
cellular uptake and disposition of, 619–620
microbiologic activity of, 564–565
pharmacodynamic models of, 567–569
application of, 573–574
pharmacodynamic(s) of, 569–570
clinical implications of, 570–573
pharmacokinetics of, 565–567

Magnetic resonance imaging (MRI), in pyelonephritis, 438

Mediastinal granuloma, in histoplasmosis, 3–4

Mediastinitis, fibrosing, in histoplasmosis, 4

Metabolic genes, in UTI pathogenesis, 267

MIC. *See Minimum inhibitory concentration (MIC).*

Micafungin, clinical pharmacology of, 177–181

Microdialysis, in antimicrobial tissue concentration measurement, 604–608

Minimum inhibitory concentration (MIC)
defined, 608
measurement of, issues related to, 608–610

Mold(s), identification of, in invasive mycosis diagnosis, 147–149

Monte Carlo simulation, in clinical pharmacodynamics of quinolones, 540–541

MRI. *See Magnetic resonance imaging (MRI).*

Mycelial fungi, in solid organ transplant recipients, 118

Mycetoma(s)
clinical manifestations of, 72–73
epidemiology of, 63–64
laboratory diagnosis of, 67–68
pathogenesis of, 66
radiologic evaluation of, 451–453
treatment of, 79–81

Mycosis(es)
invasive, laboratory diagnosis of, **135–158.** *See also Invasive mycoses, laboratory diagnosis of.*
subcutaneous, **59–85.** *See also* specific types and *Subcutaneous mycoses.*

N

Neonate(s), aminoglycosides in, 517

Nephrotoxicity, of aminoglycosides, 509

Neuromuscular blockade, by aminoglycosides, 510

Neuropathic bladder, UTIs in, 341–344

Nitrofurantoin
for acute uncomplicated cystitis, 314–316
resistance to, in acute uncomplicated cystitis, 247–248

NNRTIs. *See Nonnucleoside reverse transcriptase inhibitors (NNRTIs).*

Nonnucleoside reverse transcriptase inhibitors (NNRTIs), for HIV infection, 658

Nosocomial pneumonia, in immunosuppressed patients, **783–798**
causes of, 784–785
diagnostic tests for
bronchoscopic, 787–789
lung biopsy in, 789–790
noninvasive, 786–787
recent developments in, 785–790
thoracic CT scan in, 789
prevention of, 791–792
risk factors for, 790–791
treatment of, recent developments in, 791–793

NRTIs. *See Nucleoside reverse transcriptase inhibitors (NRTIs).*

Nucleoside reverse transcriptase inhibitors (NRTIs), for HIV infection, 657–658

Nystatin, liposomal, clinical pharmacology of, 166

O

Oligosaccharide inhibitors, in UTI prevention, 466–467

1,3-β-D-glucan, in invasive mycosis diagnosis, 152

Onychomycosis, **100–107**
clinical manifestations of, 101–106
described, 100
epidemiology of, 100–101
laboratory diagnosis of, 106
prevention of, 106–107
treatment of, 106–107

Opportunistic fungi, cytokines related to, properties of, 191–195

Oritavancin, 748

Ototoxicity, of aminoglycosides, 509

P

Pancreas transplant recipients
Aspergillus infections in, 117
Candida infections in, 117

Pararenal abscess, radiologic evaluation of, 441–443

Pelvic pain syndrome, chronic, prostatitis and, 400

Pericarditis, in histoplasmosis, 5

Perinephric abscess, UTIs and, 348–349

Perirenal abscess, radiologic evaluation of, 441–443

Pharmacodynamics, effects on breakpoint selection for susceptibility testing, **579–598.** *See also Susceptibility testing, breakpoint selection for, pharmacodynamics effects on.*

Pharmacokinetic(s), defined, 651–652

Pharmacokinetic-pharmacodynamic index, determination of, free drug level in, in breakpoint selection for susceptibility testing, 585–588

Plasma concentrations, tissue concentrations vs., 600–601

Pneumonia(s)
diffuse, coccidioidomycosis and, 45–46
hospital-acquired, **679–696.** *See also Hospital-acquired pneumonia.*
in intubated patients
dynamic concept in, 702–703
pathogen targeting in, 699–702
risk factors for, **697–705**
traditional approach to, 698–699
nosocomial, in immunosuppressed patients, **783–798.** *See also Nosocomial pneumonia, in immunosuppressed patients.*
organizing, treatment failures in patients with ventilator-associated pneumonia due to, 761
ventilator-associated, **679–696.** *See also Ventilator-associated pneumonia.*

Polyene antibiotics, clinical pharmacology of, 160–166

Polymyxin(s), **545–562**
chemical characteristics of, 546
clinical uses of, 555–559
commercial availability of, in U.S., 548
emerging resistance to, 559–560
historical perspective on, 546–548
mechanism of action of, 546–547
pharmacodynamics of, 552–555
pharmacokinetics of, 550–552
spectrum of activity of, 547
susceptibility testing for, 549–550
toxicity of, 548–549

Postmenopausal women, acute cystitis in, 325

Postpneumonectomy pulmonary edema, treatment failures in patients with ventilator-associated pneumonia due to, 762

Pregnancy
aminoglycosides during, 517–518
asymptomatic bacteriuria during, 374–376
treatment of, 339–340
coccidioidomycosis during, 54
urinary tract obstruction during, treatment of, 340–341
UTIs during, 337–341
evaluation of, 338–339
prevalence of, 337
symptomatic, treatment of, 340

Premenopausal, nonpregnant women, asymptomatic bacteriuria in, 373

Prostatitis, **395–409**
bacterial
acute, 396–397, 399
chronic, 397, 400

chronic, and chronic pelvic pain syndrome. *See Chronic prostatitis–chronic pelvic pain syndrome (CP-CPPS).*
epidemiology of, 395–396
impact of, 395–396
inflammatory, asymptomatic, 401
nonbacterial, 398
study of
discussion of, 405–407
EPS findings in, 403
inflammation detection in, specimen comparison in, 403–404
materials and methods in, 401–402
results of, 402–405
SFA findings in, 403
traditional and consensus classifications comparison in, 404–405
VB3 findings in, 403
syndromes of, classification of, 396–398
advantages of, 398
consensus, 399–401
limitations of, 398

Prostatodynia, 398

Protease inhibitors, for HIV infection, 659–662

Protectin(s), in UTI pathogenesis, 266

Protein(s), drug transport, in anti-HIV drugs, 654–655

Protein binding
in antimicrobial tissue concentrations, 601–603
in clinical pharmacodynamics of quinolones, 539–540
of anti-HIV drugs, 652–653

Pulmonary contusion, treatment failures in patients with ventilator-associated pneumonia due to, 762

Pulmonary edema, postpneumonectomy, treatment failures in patients with ventilator-associated pneumonia due to, 762

Pulmonary embolism, treatment failures in patients with ventilator-associated pneumonia due to, 761

Pulmonary hemorrhage, treatment failures in patients with ventilator-associated pneumonia due to, 761

Pyelonephritis
acute
CT in, 434–436, 438–439
in children, radiologic evaluation of, 439–441
MRI in, 438
radiologic evaluation of, **433–456**
ultrasound in, 437–438
acute uncomplicated
emerging antibiotic resistance to, 249
recurrence of, approach to, 325–326
treatment of, 321–325
emphysematous, 345–346
radiologic evaluation of, 443–445
epidemiology of, 236–237
UTIs and, 337
xanthogranulomatous, radiologic evaluation of, 447–448

Pyonephrosis, radiologic evaluation of, 445–447

Q

Quinolone(s), clinical pharmacodynamics of, **529–543**
first principles in, 529–530
Monte Carlo simulation in, 540–541
pharmacokinetic-pharmacodynamic measures in, 529–530
magnitude required for efficacy against gram-negative microorganisms, 535–536
magnitude required for efficacy against gram-positive microorganisms, 530–535
human infection data in, 533–535
in animal infection models, 532
in *in vitro* models, 530–532
magnitude required for resistance counterselection, 537–538
protein binding in, 539–540
rationale drug evaluation requirements in, 530

Quinopristin-dalfopristin, for gram-positive infections, 740–741

R

Radiologic evaluation, in UTIs, **433–456.** *See also Urinary tract infections (UTIs), radiologic evaluation of.*

Regression tree analysis, in breakpoint selection for susceptibility testing, 592

Renal abscess, radiologic evaluation of, 441–443

Renal impairment, aminoglycosides in, 514–516

Renal transplant patients, asymptomatic bacteriuria in, 381–382

Renal transplant recipients
Aspergillus infections in, 117
Candida infections in, 117

Renal tuberculosis, radiologic evaluation of, 448–451

Respiratory tract, in invasive mycosis diagnosis, 137

Ringworm, 93

S

Sepsis
abdominal, treatment failures in patients with ventilator-associated pneumonia due to, 760
urinary, treatment failures in patients with ventilator-associated pneumonia due to, 760

Siderophore(s), in UTI pathogenesis, 266

Sinusitis
microorganisms in ventilator-associated pneumonia related to, 685–686
treatment failures in patients with ventilator-associated pneumonia due to, 759

Sitafloxacin, 748

Skin blister and saliva techniques, in antimicrobial tissue concentrations measurement, 604

Small bowel transplant recipients
Aspergillus infections in, 118
Candida infections in, 118

Solid organ transplantation, recipients of, fungal infections in, **113–134.** *See also Fungal infections, in solid organ transplant recipients.*

Spinal cord–injured patients
asymptomatic bacteriuria in, 380–381
UTIs in, 341–344

Sporotrichosis
clinical manifestations of, 68–71
epidemiology of, 59–60
laboratory diagnosis of, 66–67
pathogenesis of, 64–65
treatment of, 73–76

Stool sample, in invasive mycosis diagnosis, 138

Subcutaneous mycoses, **59–85**
clinical manifestations of, 68–73
chromoblastomycosis, 71–72
mycetoma, 72–73
sporotrichosis, 68–71
epidemiology of, 60–64
chromoblastomycosis, 60–62
mycetoma, 62–63
sporotrichosis, 59–60
laboratory diagnosis of, 66–68
chromoblastomycosis, 67
mycetoma, 67–68
sporotrichosis, 66–67
pathogenesis of, 64–66
chromoblastomycosis, 65–66
sporotrichosis, 64–65
treatment of, 73–81
chromoblastomycosis, 76–79
mycetoma, 79–81
sporotrichosis, 73–76

Superinfection, treatment failures in patients with ventilator-associated pneumonia due to, 758

Suprapubic catheters, in prevention of catheter-associated UTIs, 422–424

Susceptibility testing, breakpoint selection for classification in, 592
Monte Carlo simulation in, 588–592
pharmacodynamic effects on, **579–598**
concentration–effect relationships of antimicrobials, 581–584
in antimicrobial development, 592–594
in Europe, 580–581
in U.S., 580
pharmacokinetic(s)-pharmacodynamic(s) in, 584–585
pharmacokinetic-pharmacodynamic index determination in, free drug level for, 585–588
regression tree analysis in, 592

T

Terbinafine, for chromoblastomycosis, 78–79

Th1 cytokines, 193–194

Th2 cytokines, 194

Thoracic CT scan, for nosocomial pneumonia in immunosuppressed patients, 789

Tigecycline, 747

Tinea barbae, 98

Tinea capitis, 95–96

Tinea corporis, 93

Tinea cruris, 94

Tinea faciei, 97–98

Tinea incognito, 97–98

Tinea manuum, 96–97

Tinea pedis, clinical forms of, 89–93

Tinea versicolor, **107–109**
clinical manifestations of, 107
described, 107
epidemiology of, 107
host defense in, 107
laboratory diagnosis of, 108
pathogenesis of, 107
prevention of, 109
treatment of, 109

Tissue biopsy, in invasive mycosis diagnosis, 137

Tissue concentrations
antimicrobial, **599–613.** *See also Antimicrobial tissue concentrations.*
free tissue, measurement of, techniques for, 603–608
plasma concentrations vs., 600–601

TLR4 signaling, in host response to UTIs, 286–287

Toxin(s), in UTI pathogenesis, 266

TPM-SMX. *See Trimethoprim-sulfamethoxazole (TMP-SMX).*

Transfusion(s), granulocyte. *See Granulocyte transfusions.*

Transplantation, coccidioidomycosis in patients undergoing, 54

Treatment failure
defined, 753–754
in patients with ventilator-associated pneumonia, **753–769.** *See also Pneumonia(s), ventilator-associated, treatment failures in patients with.*

Triazole(s)
antifungal. *See Antifungal triazoles.*
pharmacodynamic parameter magnitude of, 640–644

Trimethoprim-sulfamethoxazole (TMP-SMX)
for acute uncomplicated cystitis, 312–313
resistance to, in acute uncomplicated cystitis, 244–246

predictors of infection or colonization with, 310

Tuberculosis
genitourinary, UTIs resulting from, 346–348
renal, radiologic evaluation of, 448–451

U

Ultrasound, in pyelonephritis, 437–438

Urea-splitting organisms, UTIs resulting from, 346

Urinalysis, in invasive mycosis diagnosis, 137–138

Urinary catheters
misuse of, 416–417
use of, 416–417

Urinary diversion, UTIs in patients with, 344

Urinary sepsis, treatment failures in patients with ventilator-associated pneumonia due to, 760

Urinary tract, obstruction of, UTIs and, 336–337

Urinary tract infections (UTIs). *See also* specific infections, e.g., *Cystitis.*
asymptomatic bacteriuria preceding, 235–236
catheter-associated, **411–432**
biofilms and, 413–415
clinical manifestations of, 417–418
management of, 418
microbiology of, 416
morbidity related to, 411–412
mortality related to, 411–412
patient discomfort with, 412
prevalence of, 411
prevention of, 419–424
alternate methods for urinary collection in, 421–424
anti-infective catheters in, 420–421
aseptic insertion in, 420
avoiding indwelling catheter in, 419–420
catheter care in, 420
closed drainage in, 420
discontinuing indwelling catheter in, 419–420
ineffective practices in, 424
systemic antimicrobials in, 421
risk factors for, 415–416
causes of, 227

Urinary (*continued*)
community-acquired
causes of, 304
in young healthy men, 326–327
treatment of, **303–332**
urine cultures in, 325
complicated
antibiotic resistance to
clinical implications of, 252–253
determinants of, 251–252
defined, 304, 333
emerging antibiotic resistance to, 249–251
evaluation of, 334–335
management of, **333–351**
initial, 333–334
medical, 335
pyelonephritis and, 337
urinary tract obstruction and, 336–337
costs related to, 237
defenses against, 459
during pregnancy, 337–341. *See also Pregnancy, UTIs during.*
Echinococcus and, 348
epidemiology of, **227–241,** 458
genitourinary tuberculosis and, 346–348
hospitalizations resulting from, 333
host response to, **279–302**
genetic determinants of, 286–287
genetic tools in identification of risk patients, 292–293
IL-8 receptor knock-out and, 287
SNPs in human CXCR1 gene, 290–291
strengthening of
blocking of TLR4-dependent signaling in, 293
enhancement of neutrophil function in CXCR1-deficient patients, 294
induction of ABU in patients with recurrent symptomatic UTIs, 294–296
inhibitors of GSL receptor expression in, 293
new approaches to, 293–297
UTI vaccines and specific immunity in, 296–297
TLR4 expression and, 292
TLR4 signaling in, 286–287
two-step model for, 280–286
initiation of host response in, 281–284
neutrophil recruitment and bacterial clearance in, 285–286
in diabetics, 344–345
in infants and children, **353–365**
clinical manifestations of, 355
diagnosis of, 355–357
entobacteriaceae and, 354–355
host defense factors and, 354
imaging of, 358–359
incidence of, 353
outcome following, 359–360
prevention of, 360–361
recurrence rates for, 353–354
treatment of, 357–358
in neuropathic bladder, 341–344
in spinal cord–injured patients, 341–344
in urinary diversion, 344
incidence of, 237
natural history of, 305–306
pathogenesis of, 458–459
microbial virulence determinants and, **261–278**
adhesions, 262–265
clinical relevance of, 271–272
combinations of, 267–269
diversity of, 267–269
evolutionary considerations related to, 270–271
extraintestinal pathogenic *Escherichia coli*, 261–262
future prospects for, 273
lipopolysaccharide, 267
metabolic genes, 267
organisms causing, 272–273
protectins, 266
redundancy of, 267–269
siderophores, 266
toxins, 266
virulence factor expression in, 269–270
virulence factor transmission in, 270
virulence factor variants in, 269–270
pathogens of, antibiotic resistance to
emerging, **243–259.** *See also Antibiotic resistance, emerging, in urinary tract pathogens.*
in acute uncomplicated pyelonephritis, 249
issues related to, 254–255
multi-drug–related, 254–255
patients at risk for, genetic tools in identification of, 292–293
perinephric abscess resulting from, 348–349
prevention of, **457–471**
bacterial colonization of bladder in, 466
cranberry products in, 459–462
lactobilli in, 462–464

normal vaginal flora in, 459
oligosaccharide inhibitors in, 466–467
vaccines in, 464–465
radiologic evaluation of, **433–456**
pararenal abscesses, 441–443
percutaneous, 453
perirenal abscesses, 441–443
renal abscesses, 441–443
risk factors for, 229–235
transmission of, 227–228, 237
treatment of, principles of, 306–307
uncomplicated
defined, 304
described, 333
unresolved
bacterial persistence in, 335–336
during therapy, causes of, 335
unusual organisms causing, 346–348
urea-splitting organisms causing, 346
uropathogenesis of, 228–229
vaccines for, in host response strengthening, 296–297

Urinary tract obstruction, during pregnancy, treatment of, 340–341

Urine cultures
in uncomplicated cystitis, 325
in uncomplicated pyelonephritis, 325

Urologic devices, asymptomatic bacteriuria in persons with, 383–385

UTIs. *See Urinary tract infections (UTIs).*

V

Vaccine(s)
for coccidioidomycosis, development of, 55
in UTI prevention, 464–465

Vancomycin-resistant enterococci, in complicated UTIs, 249–250

Ventilator-associated pneumonia, **679–696, 707–716.** *See also Hospital-acquired pneumonia.*
bacteriologic aspects of, 709–710
diagnosis of
clinical criteria in, 710–711
evaluation of techniques in, 711–713
future investigations in, 713–714
postmortem studies, limitations of, 713
histopathology of, 709–710
microorganisms in, 680–691
classification of, 681
sources of, 682
blood-related, 689–690
endogenous, 684–690
exogenous, 690–691
gastric colonization, 687–688
humidifiers, 690–691
mouth colonization, 686–687
nasal carriers, 684–685
nebulizers, 690–691
oropharynx colonization, 687–688
sinusitis, 685–686
tracheal colonization, 688–689
tracheal tube biofilm, 690
ventilator circuits, 690–691
treatment failures in patients with, **753–769**
abdominal sepsis and, 760
abscess and, 759
antibiotics and, 758
ARDS and, 761
atelectasis and, 760–761
catheter-related infection and, 760
causes of, 756–763
CHF and, 761
concomitant foci of infection and, 759–760
drug-related fever and, 762
empyema and, 759
host response–related, 762–763
investigations of, 764–766
noninfectious conditions and, 760–762
organizing pneumonia and, 761
pathogen-related, 757–758
patterns of, 763–764
postpneumonectomy pulmonary edema and, 762
pulmonary contusion and, 762
pulmonary embolism and, 761
pulmonary hemorrhage and, 761
sinusitis and, 759
superinfection and, 758
suppurative bronchitis and, 759
urinary sepsis and, 760
treatment response to
evaluation of, criteria for, 755–756
time course of, 754–755

Vestibular toxicity, of aminoglycosides, 510

Virulence factor(s), in UTI pathogenesis
clinical relevance of, 271–272
combinations of, 267–269
diversity of, 267–269
redundancy of, 267–269

Virulence factor expression, in UTI pathogenesis, regulation of, 269–270

Virulence factor variants, in UTI
pathogenesis
regulation of, 269–270
transmission of, 270

Voriconazole, clinical pharmacology of, 176–177

W

Weight
as factor in aminoglycoside dosing, 513–514
dosing by, administration rate in, 514

Wound(s), in invasive mycosis diagnosis, 138

X

Xanthogranulomatous pyelonephritis, radiologic evaluation of, 447–448

Y

Yeast(s), identification of, in invasive mycosis diagnosis, 147–149